Search research articles
Contact Us
Filters
Showing results (31-40 of 38) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 38 results.
Radiation Oncology (London, England)
|
December 9, 2015
Consecutive magnetic resonance imaging during brachytherapy for cervical carcinoma: predictive value of volume measurements with respect to persistent disease and prognosis
J E Mongula, B F M Slangen, D M J Lambregts, et al.
Journal of Cancer Research and Clinical Oncology
|
January 20, 2021
Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort
S Thijssen, H Wildiers, K Punie, et al.
BMC Cancer
|
February 22, 2016
TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial
M M Koeneman, A J Kruse, L F S Kooreman, et al.
Gynecologic Oncology
|
September 30, 2020
Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors
C Landolfo, E T L Achten, J Ceusters, et al.
Gynecologic Oncology
|
May 11, 2023
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer
I Vergote, E Van Nieuwenhuysen, A Casado, et al.
BMC Cancer
|
February 9, 2017
Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial
M M Koeneman, A J Kruse, L F S Kooreman, et al.
ESMO Open
|
May 20, 2025
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib
L Beltrame, L Mannarino, A Sergi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
T Van Gorp, D Cibula, W Lv, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 38) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 38 results.
Radiation Oncology (London, England)
|
December 9, 2015
Consecutive magnetic resonance imaging during brachytherapy for cervical carcinoma: predictive value of volume measurements with respect to persistent disease and prognosis
J E Mongula, B F M Slangen, D M J Lambregts, et al.
Journal of Cancer Research and Clinical Oncology
|
January 20, 2021
Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort
S Thijssen, H Wildiers, K Punie, et al.
BMC Cancer
|
February 22, 2016
TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial
M M Koeneman, A J Kruse, L F S Kooreman, et al.
Gynecologic Oncology
|
September 30, 2020
Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors
C Landolfo, E T L Achten, J Ceusters, et al.
Gynecologic Oncology
|
May 11, 2023
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer
I Vergote, E Van Nieuwenhuysen, A Casado, et al.
BMC Cancer
|
February 9, 2017
Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial
M M Koeneman, A J Kruse, L F S Kooreman, et al.
ESMO Open
|
May 20, 2025
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib
L Beltrame, L Mannarino, A Sergi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
T Van Gorp, D Cibula, W Lv, et al.
Page
of 4